A61P 31/20
For dna viruses
Official title: for DNA viruses
A61P31/20 (For dna viruses) appears on 6,416 US grants and 10,015 published applications in this corpus.
Search patents in A61P- Granted patents
- 6,416
- Published applications
- 10,015
- Assignees
- 3,465
- Inventors
- 16,600
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 4 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 5 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 6 | 0 |
| 1992 | 6 | 0 |
| 1993 | 12 | 0 |
| 1994 | 12 | 0 |
| 1995 | 23 | 0 |
| 1996 | 26 | 0 |
| 1997 | 35 | 0 |
| 1998 | 72 | 0 |
| 1999 | 77 | 0 |
| 2000 | 83 | 0 |
| 2001 | 122 | 31 |
| 2002 | 136 | 178 |
| 2003 | 124 | 301 |
| 2004 | 95 | 334 |
| 2005 | 112 | 376 |
| 2006 | 132 | 309 |
| 2007 | 163 | 410 |
| 2008 | 162 | 370 |
| 2009 | 207 | 497 |
| 2010 | 255 | 660 |
| 2011 | 273 | 568 |
| 2012 | 360 | 566 |
| 2013 | 309 | 440 |
| 2014 | 401 | 416 |
| 2015 | 316 | 406 |
| 2016 | 317 | 434 |
| 2017 | 345 | 409 |
| 2018 | 332 | 426 |
| 2019 | 350 | 463 |
| 2020 | 304 | 412 |
| 2021 | 298 | 384 |
| 2022 | 231 | 378 |
| 2023 | 183 | 442 |
| 2024 | 186 | 342 |
| 2025 | 200 | 279 |
| 2026 | 120 | 184 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of treating influenza and poxvirus viral infections6 Oct 2026US 12,751,942 B2Veru Inc.
- Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses6 Oct 2026US 12,753,187 B2Merck Sharp & Dohme Corp.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Compositions and methods related to human neutralizing antibodies to hepatitis B29 Sep 2026US 12,747,283 B2The Rockefeller University
- Treatment of herpes zoster with topical tetracaine22 Sep 2026US 12,740,960 B2Pagari Life Science Corp
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Pharmaceutical composition for the treatment and prevention of hpv1 Oct 2026US 2026/0294864 A1Np1 Srl
- Oral pharmaceutical compositions1 Oct 2026US 2026/0294910 A1Assembly Biosciences, Inc.
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- Oligonucleotides comprising segmented gap structures1 Oct 2026US 2026/0297584 A1Ausperbio Therapeutics Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Sustained release drug delivery devices360US 5,902,598 AControl Delivery Systems, Inc. · 1999
- Immunomodulatory oligonucleotides335US 6,194,388 B1Coley Pharmaceutical Group, Inc. · 2001
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009